Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech company developing novel immunotherapies for cancer treatment, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Robert Connelly will present on September 11, 2024, at 2:30 p.m. ET. The presentation will be available via live webcast and on-demand for 90 days afterward.

Elicio specializes in lymph node-targeted immunotherapies using their proprietary AMP technology. This approach aims to enhance the immune system's cancer-fighting capabilities by delivering therapeutic payloads directly to lymph nodes. Their R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002 (for mKRAS-driven cancers), ELI-007, and ELI-008 (for BRAF-driven cancers and p53 hotspot mutations, respectively).

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 2:30 p.m. ET.

A live webcast of the presentation will be accessible to registered attendees via Elicio’s Events page. An archived replay will be available on-demand for 90 days following the event.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. Elicio’s R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com.

Investor Relations Contact
Brian Piekos
Elicio Therapeutics
IR@elicio.com
857-209-0153

FAQ

When is Elicio Therapeutics (ELTX) presenting at the H.C. Wainwright Global Investment Conference?

Elicio Therapeutics (ELTX) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 2:30 p.m. ET.

What is the focus of Elicio Therapeutics' (ELTX) research and development?

Elicio Therapeutics (ELTX) focuses on developing lymph node-targeted immunotherapies for cancer treatment using their AMP technology, which delivers therapeutic payloads directly to lymph nodes to enhance the immune system's cancer-fighting capabilities.

What cancer vaccines are in Elicio Therapeutics' (ELTX) R&D pipeline?

Elicio Therapeutics' (ELTX) R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002 (targeting mKRAS-driven cancers), ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively).

How can investors access Elicio Therapeutics' (ELTX) presentation at the H.C. Wainwright conference?

Investors can access a live webcast of Elicio Therapeutics' (ELTX) presentation via the company's Events page. An archived replay will be available on-demand for 90 days following the event.